This year has seen a double dose of optimism in the field of HIV prevention. First, on 20 June 2024, came the results of the Purpose-1 trial in South Africa and Uganda.1 This randomised controlled ...

Gilead Sciences’s decision to distribute HIV prevention drug lenacapavir made the news this month when they signed ...

New data from the PURPOSE 2 trial continue to show the efficacy of lenacapavir in HIV prevention in individuals who have sex ...

GILD's recent upbeat data on lenacapavir underscore the investigational drug???s potential to prevent HIV in the targeted ...

The twice yearly lenacapavir injection will be available in 120 countries with a series of regulatory filings beginning by ...

US antivirals specialist Gilead Sciences has released additional data from its pivotal Phase III PURPOSE 2 trial providing an ...

Gilead Sciences Inc. (GILD) announced that additional data from its pivotal Phase 3 PURPOSE 2 trial demonstrated a 96% reduction in ...

We welcome Gilead’s statement of commitment to non-profit pricing, but we had been waiting eagerly for a specific price. We ...

Dr. Reddy's, Hetero, and Mylan partner with Gilead Sciences to manufacture generic lenacapavir for HIV prevention globally.

Lenacapavir, a bi-annual injectable treatment for HIV prevention (PrEP), is being celebrated as a major advancement in the field following new study results showing a 96% reduction in HIV cases.

(RTTNews) - Gilead Sciences, Inc. (GILD) Wednesday said it has signed royalty-free licensing agreements with six pharmaceutical manufacturers to manufacture and supply generic versions of the ...

Gilead plans to supply lenacapavir to generic manufacturers, priced at no-profit to the company, until they fully support demand. The agreements also cover lenacapavir for HIV prevention that is ...